A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlodipine 10 mg in patients with essential hypertension not adequately controlled with amlodipine 5 mg alone
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Amlodipine/valsartan (Primary) ; Amlodipine
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 01 Feb 2009 Results have been published in the International Journal of Clinical Practice.
- 24 Jul 2008 Status change
- 19 Jun 2008 Status change from in progress to completed